Telix partners with Ekalia to develop US astatine-211 production
TLX•Telix Pharmaceuticals partnered with Ekalia to develop scalable U.S. astatine-211 production, securing priority isotope access for its alpha therapy pipeline. The first IBA alpha-beam cyclotron is planned for installation at an RLS Radiopharmacies site near Philadelphia.
1. Production collaboration
Telix Pharmaceuticals partnered with Ekalia, an IBA-Framatome joint venture, to develop scalable U.S. astatine-211 production and secure long-term, priority isotope access for its alpha therapy pipeline, including TLX102-Tx for glioblastoma and leptomeningeal disease.
2. First installation planned
The first IBA alpha-beam cyclotron will be installed at the RLS Radiopharmacies site in Trevose, near Philadelphia. The partners will evaluate additional RLS installations as demand develops, and production capacity is also intended for third-party academic and industry programs.
